Skip to main content
SpringerLink
Log in

Pharmacokinetic–pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies

  • Brief Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Voriconazole has been shown to be safe and effective for fungal infection. However, its population pharmacokinetics for patients with hematological malignancies remains unknown. We performed a population pharmacokinetics study of nine hematological patients with 36 points samples. We approximated the drug concentration curve using a linear one-compartment model. The distribution of volume (Vd), elimination rate constant, and clearance (CL) were 68.7 L, 0.163 h−1, and 11.2 L/h, respectively. By coincidence, our study has verified that the current administration is enough to treat fungus infections by using Monte Carlo simulation. Our data demonstrated that the current administration method is appropriate and effective. Our results may prove to be useful as a basic reference for the clinical usage of voriconazole.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a, b

References

  1. Walsh TJ, Pappas P, Winston DJ et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234

    Article  PubMed  CAS  Google Scholar 

  2. Andes D, Marchillo K, Stamstad T et al (2003) In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47:3165–3169

    Article  PubMed  CAS  Google Scholar 

  3. Nomura K, Morikawa N, Ikawa K et al (2008) Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother 61:892–900. doi:10.1093/jac/dkn038

    Article  PubMed  CAS  Google Scholar 

  4. Levêque D, Nivoix Y, Jehl F et al (2006) Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 27:274–284

    Article  PubMed  Google Scholar 

  5. Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75:85–94

    Article  PubMed  Google Scholar 

  6. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241–57

    Article  PubMed  Google Scholar 

  7. Pfaller MA, Jones RN, Doern GV et al (1999) International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 35:19–25

    Article  PubMed  CAS  Google Scholar 

  8. Pfaller MA, Messer SA, Hollis RJ et al (2002) In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46:1723–1727

    Article  PubMed  CAS  Google Scholar 

  9. Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45:649–663

    Article  PubMed  CAS  Google Scholar 

  10. Ikeda Y, Umemura K, Kondo K et al (2004) Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 75:587–588

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We wish to express our special thanks to Professor Tatsuya Takagi and Assistant Professor Kousuke Okamoto (Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan) for their pharmacological advice.

Funding

None.

Competing interests

None.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kawaramachi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan

    K. Nomura, Y. Fujimoto & M. Taniwaki

  2. Department of Microbiology, Kyoto Prefectural Institute of Public Health and Environment, Kyoto, Japan

    K. Nomura

  3. Department of Hospital Pharmacy, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Y. Kanbayashi

  4. Department of Clinical Pharmacotherapy, Hiroshima University, Hiroshima, Japan

    K. Ikawa

  5. Department of Clinical Molecular Genetics and Laboratory Medicine, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan

    M. Taniwaki

Authors
  1. K. Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Kanbayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Ikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Taniwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Nomura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nomura, K., Fujimoto, Y., Kanbayashi, Y. et al. Pharmacokinetic–pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 27, 1141–1143 (2008). https://doi.org/10.1007/s10096-008-0543-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-008-0543-1

Keywords

Search

Navigation